What is the rate of significant gastrointestinal problems resulting from prostaglandin therapy?

The rate of significant gastrointestinal problems associated with prostaglandin therapy is reported to be about 10%. This aligns with clinical observations that have documented gastrointestinal side effects occurring in this range. Prostaglandins can stimulate gastric acid secretion and affect gastrointestinal motility, which may lead to complications, especially in certain populations or when used at higher doses.

Understanding this percentage is crucial for clinicians when prescribing prostaglandin therapy, as it highlights the need for careful monitoring for gastrointestinal issues. This knowledge allows healthcare providers to better inform patients about potential side effects and discuss management strategies if they occur, balancing the benefits of prostaglandin therapy with the risks of gastrointestinal effects.